Trial Search Results

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:


Collaborator: Forest Laboratories

Stanford Investigator(s):


  • Drug: CAZ-AVI
  • Drug: Metronidazole
  • Drug: Meropenem


Phase 3


Inclusion Criteria:

   - 18 to 90 years of age inclusive

   - Female patient is authorized to participate if at least one of the following criteria
   are met:

      1. Surgical sterilization

      2. Age ≥50 years and postmenopausal as defined by amenorrhea for 12 months or more
      following cessation of all exogenous hormonal treatments

      3. Age <50 years and postmenopausal as defined by documented LH and FSH levels in
      the postmenopausal range PLUS amenorrhea for 12 months or more following
      cessation of all exogenous hormonal treatments

      4. Patient has a negative serum pregnancy test (serum ß-human chorionic gonadotropin
      [ß-hCG]) within 1 day prior to study entry, and agrees to use highly effective
      contraception methods during treatment and for at least 7 days after last dose of
      IV study therapy

   - Intraoperative/postoperative enrollment with confirmation (presence of pus within the
   abdominal cavity) of an intra-abdominal infection associated with peritonitis

   - Confirmation of infection by surgical intervention within 24 hours of entry: evidence
   of systemic inflammatory response; physical findings consistent with intra-abdominal
   infection; supportive radiologic imaging findings of intra-abdominal infections

Exclusion Criteria:

   - Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12
   hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other
   intra-abdominal processes in which primary etiology is not likely to be infectious

   - Patient has abdominal wall abscess or bowel obstruction without perforation or
   ischemic bowel without perforation

   - Patient has suspected intra-abdominal infections due to fungus, parasites, virus or

   - Patient is considered unlikely to survive the 6 to 8 week study period or has a
   rapidly progressive or terminal illness, including septic shock that is associated
   with a high risk of mortality

Ages Eligible for Study

18 Years - 90 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Valerie Ojha
Not Recruiting